Immunosuppression, Pneumococcal Vaccines
Conditions
Keywords
immunosuppression, pneumococcal vaccines
Brief summary
The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster with of 21-valent pneumococcal conjugate vaccine . Immune response will be assessed by opsonophagocytic assay reactivity.
Detailed description
Recommendations for optimal vaccination strategies in immunocompromised patients has been limited. Strategies focused on utilizing a conjugate vaccine alone, as either initial vaccination or booster dosing, have not demonstrated significant increased antibody expression in immunocompromised patients\[7\]. Strategies where immunocompromised patients were vaccinated with a conjugate vaccine followed by polysaccharide vaccine have demonstrated that 50% of individuals achieve functional antibodies\[7\]. Since improved antibody response in naive patients has been seen in combination vaccination, we aim to test this strategy for boosting in previously vaccinated immunocompromised patients. The 15 valent Pneumococcal Conjugate Vaccine (PCV15) is available for use in adults and contains S. Pneumoniae serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F \[5\]. In this study we postulate that booster dosing with PCV21 in immunocompromised adults who are at least 5 years from receipt of PPSV23 will elicit a strong immune response represented by change in serotype specific OPA GMT from baseline to 4 weeks post booster vaccine completion. We will specifically evaluate the change in pneumococcal opsonophagocytic activity at baseline to 6 months (Pn-OPA) for S. Pneumoniae serotypes 3, 6A, 15A, 19A, 20A, 23A, 31, 35B, 9n, 11A, and 22F. These specific serotypes have been selected due to current disease burden trends, to address current gaps in data, and have been identified as the most relevant for PCV development underway.
Interventions
DRUG21-valent pneumococcal conjugate vaccine
FDA approved pneumococcal vaccines 21 valent conjugate vaccine administered at enrollment
Sponsors
Merck Sharp & Dohme LLC
VA Sierra Nevada Health Care System
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Subject meets the CDC definition of an immunocompromising condition o chronic renal failure, congenital or acquired asplenia, generalized malignancy, HIV infection, Hodgkin disease, iatrogenic immunosuppression, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, sickle cell disease or other hemoglobinopathies, and solid organ transplant. * Have received at least 1 dose of PPSV23
Exclusion criteria
* Less than 5 years since last receipt of PPSV23 validated to patient medical record and Immunize Nevada Website * Previous administration of PCV20 * Previous administration of PCV13 * Previous administration of PCV15 * Less than 14 days since administration of any COVID19 vaccination * Previous history of Invasive Pneumococcal Disease (IPD) * Antibiotic treatment within the previous 90 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in opsonophagocytic assay (OPA) geometric mean titers (GMT) | 24 months | Evaluation of the change fold increase in S. Pneumonia OPA GMT from baseline to 24 weeks after the administration of a pneumococcal vaccine booster series consisting of PCV15 followed by PPSV23 8 weeks later for S. Pneumoniae serotypes 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F |
Outcome results
None listed